NCT03228368Unknown不适用
The Predicted Potential of Quantitative T Cell Repertoire(TCR) Analysis Using Next-generation Sequencing (NGS) in Anti-PD-L1 Treatment in Non Small Cell Lung（NSCLC) Cancer Patients
First Affiliated Hospital of Zhejiang University1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2017年3月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- T cell repertoire
研究概览
简要总结
This study is designed to evaluate the predicted potential of quantitative T cell repertoire (TCR) of T cell receptor chains using next-generation sequencing (NGS) in the treatment of the anti-programmed death-ligand 1 (PD-L1) antibody atezolizumab in participants with locally advanced or metastatic NSCLC who have progressed during or following a platinum-containing regimen. Treatment may continue until disease progression or unacceptable toxicity.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically documented, locally advanced or metastatic NSCLC
- •Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens available or at least 12 unstained, freshly cut serial sections with associated pathology report that are evaluable for PD-L1 expression and epidermal growth factor receptor (EGFR) mutation status prior to enrollment, except for known sensitizing EGFR mutations in which case 10 unstained slides are required and there is no need for central testing of EGFR mutation status
- •Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable, inoperable, or metastatic NSCLC, or disease recurrence within 6 months of treatment with a platinum-based adjuvant and/or neoadjuvant regimen or combined modality with curative intent
- •Measurable disease per RECIST Version 1.1
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Life expectancy greater than or equal to (>/=) 12 weeks
- •Adequate hematologic and end organ function
- •Agreement to remain abstinent or use contraceptive methods among women of childbearing potential or male partners of women of childbearing potential
- •Recovery from all acute toxicities from previous therapy
排除标准
- •Active or untreated central nervous system (CNS) metastases
- •Spinal cord compression not definitively treated or not clinically stable
- •Leptomeningeal disease
- •Uncontrolled pleural or pericardial effusions or ascites requiring recurrent drainage
- •Uncontrolled tumor-related pain
- •Uncontrolled hypercalcemia
- •Malignancies other than NSCLC within 5 years prior to randomization, except for those curatively treated with negligible risk of metastasis or death
- •Pregnant or lactating women
- •Significant cardiovascular, pulmonary, or autoimmune disease
- •Severe infection or major surgery within 4 weeks, or antibiotic treatment within 2 weeks prior to randomization
- •Prior treatment with or hypersensitivity to study drug(s) or related compounds
- •Inability to discontinue strong cytochrome P450 (CYP) 3A4 inhibitors
- •Prior allogeneic bone marrow or solid organ transplant
- •Known PD-L1 expression status from other clinical studies
- •Positive human immunodeficiency virus (HIV) or hepatitis B or C
- •Receipt of a live attenuated vaccine within 4 weeks prior to randomization
- •Treatment with systemic immunomodulators within 4 weeks or five half-lives (whichever is shorter) prior to randomization
- •Treatment with systemic corticosteroids within 2 weeks prior to randomization
研究组 & 干预措施
Atezolizumab (MPDL3280)
Atezolizumab 1200 milligrams (mg) will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
干预措施: Atezolizumab (MPDL3280A) (Drug)
结局指标
主要结局
T cell repertoire
时间窗: From Screening until disease progression, death, or loss to follow-up (up to approximately 3 years overall)
Change of T cell receptor repertoire during Anti-PL-L1 treatment.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade GliomasHigh Grade GliomaNCT02041611Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins20
已完成
不适用
Prognostic Value of Divpenia and CD4 Count in Relapsed Breast or Lung Cancer PatientsBreast CancerLung CancerNCT01306188Centre Leon Berard179
已完成
不适用
Quantitative and qualitative analysis of T cells infiltrating the skin of children suffering from graft-versus-host diseasetransplantatieziekte (GvHD)GvHDGraft-versus-Host DiseaseNL-OMON37587niversitair Medisch Centrum Utrecht40
招募中
不适用
A prospective observational study of T cell subsets after administration of immune checkpoint inhibitors in patients with lung cancerung cancerJPRN-UMIN000043565Kobe City Medical Center General Hospital50
已完成
不适用
Latent Tuberculosis Infection in Bone Marrow Transplant RecipientsTuberculosisNCT01021124Asan Medical Center409